Aptevo Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $3.1M | $12.3M | $4.3M | $32.4M |
| Cost of Revenue | — | — | — | — | — | — | — | $19.9M |
| Gross Profit | — | — | — | — | — | — | — | $12.5M |
| Gross Margin | — | — | — | — | — | — | — | 38.5% |
| Operating Expenses | ||||||||
| Research & Development | — | $14.5M | $14.4M | $17.1M | $17.9M | $19.0M | $17.9M | $24.8M |
| SG&A Expense | — | $11.8M | $10.2M | $11.8M | $13.9M | $14.7M | $14.0M | $25.3M |
| Operating Income | — | $-26.3M | $-24.6M | $-28.9M | $-28.6M | $-21.4M | $-27.5M | $-41.0M |
| Operating Margin | — | — | — | — | -919.7% | -174.1% | -638.1% | -126.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-26.0M | $-24.1M | $-18.7M | $7.0M | $-29.4M | $-30.9M | $-43.1M |
| Income Tax Expense | — | $0 | — | — | — | — | — | — |
| Net Income | — | $-26.0M | $-24.1M | $-17.4M | $8.0M | $-28.5M | $-17.8M | $-40.4M |
| Net Margin | — | — | — | — | 257.8% | -231.5% | -411.9% | -124.7% |
| EPS (Basic) | — | $-87.27 | $-31,460.23 | $-2,316.83 | $0.79 | $-3.04 | $-2.62 | $-6.93 |
| EPS (Diluted) | — | $-87.27 | $-31,460.23 | $-2,316.83 | $0.79 | $-3.04 | $-2.62 | $-6.93 |
| Shares Outstanding (Basic) | 1.2M | 315.5K | 276.1K | 12.2M | 10.2M | 9.4M | 8.8M | 6.5M |
| Shares Outstanding (Diluted) | 1.2M | 315.5K | 276.1K | 12.2M | 10.2M | 9.4M | 8.8M | 6.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |